AgeX Therapeutics
(NYSEMKT) AGE
AgeX Therapeutics Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$130.00K
Net Income (TTM)
$19.44M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
AGE News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout AgeX Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
16
CEO
Steven A. Ledger
Website
www.serinatherapeutics.comHeadquarters
Alameda, CA 94501, US
AGE Financials
Key Financial Metrics (TTM)
Gross Margin
44%
Operating Margin
-185%
Net Income Margin
-148%
Return on Equity
-15%
Return on Capital
-7%
Return on Assets
-3%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$0.00
Operating Income
$24.02M
EBITDA
$24.02M
Operating Cash Flow
$17.95M
Capital Expenditure
$0.00
Free Cash Flow
$17.95M
Cash & ST Invst.
$3.06M
Total Debt
$196.00K
AgeX Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
+100.0%
Gross Profit
$0.00
+100.0%
Gross Margin
0.00%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
4
N/A
Net Income
$3.59M
+56.8%
EBITDA
$6.21M
-1228.5%
Quarterly Fundamentals
Net Cash
$2.86M
-16.0%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$196.00K
-26.9%
Short Term Debt
$0.00
N/A
Return on Assets
-2.76%
N/A
Return on Invested Capital
-7.09%
N/A
Free Cash Flow
$6.03M
+48.3%
Operating Cash Flow
$6.03M
+48.2%